Q2 earnings beat, raised 2026 guidance, and $100M buyback ignite LFST

 

 11.5% surge

• LifeStance reported Q2 revenue of $435.4M, +26% YoY and beating estimates of ~$415M (per earnings release and MarketBeat).
• Turned profitable with net income $23.6M vs prior-year loss; Adj. EBITDA surged 94% to $66M (15.2% margin).
• Clinician base grew 11% to 8,542; visit volumes rose 19% to 2.6M, showing strong operational momentum.
• Raised full-year 2026 outlook for revenue ($1.685-1.725B), Center Margin, and Adj. EBITDA ($215-235M).
• Announced new $100M share repurchase program, signaling board confidence in valuation and cash flow ($88M FCF in Q2).
• Analysts responded positively (e.g., BTIG raised PT to $16 from $15, Maintain Buy); stock broke to new highs on continued buying.
• Modest initial reaction post-Aug 6 release gave way to momentum buying and estimate revisions by Aug 10.

https://finviz.com/stock?t=LFST&p=d